View Older Stories View More Recent Stories
-
MacroGenics Announces Pricing of Public Offering of Common Stock
-
Roth Keeps Regeneron (REGN) at 'Buy' Following Q4 Numbers, Outlook; VISTA, OUTLOOK Still in Focus
-
Notable Analyst Rating Changes 02/12: (CROX) (S) (ZTS) Upgraded; (AMZN) (DF) (GMCR) Downgraded
-
Pre-Open Stock Movers 2/12: (OC) (CSTE) (TRIP) Higher; (VTUS) (RLOC) (PRGN) Lower (more...)
-
Roth Capital Starts Rally Software Development (RALY) at Buy
-
Roth Capital Starts Orion Energy Systems (OESX) at Buy
-
Roth Capital Lifts PT on Ligand (LGND) to $92; Still Sees Plenty of Positive Catalysts Ahead
-
Canadian Solar (CSIQ) Prices 2.78M Common, $130M Convertible Notes Offering
-
Roth Capital Downgrades Insperity (NSP) to Neutral
-
MacroGenics Announces Proposed Public Offering of Common Stock
-
Streetinsider.com's Hot Lunchtime Reads 02/07: (PG) (ANGI) (SODA) (PTEN)
-
SodaStream (SODA)/ Pepsi (PEP) Deal is Unlikely, Says Roth Capital
-
Pyramid Oil (PDO) and Yuma Enter Merger Pact
-
Roth Capital Reaffirms Spectrum (SPPI) at Buy; FDA Grants Beleodaq NDA Priority Review
-
Top Image Systems, Ltd. Closes $15.0 Million Public Offering of Ordinary Shares Including Exercise in Full of Overallotment Option
-
Notable Analyst Rating Changes 02/04: (ZNGA) (MRK) (WETF) Upgraded; (HP) (NEM) (TTWO) Downgraded
-
Roth Capital Starts Kindred Biosciences (KIN) at Buy
-
Roth Capital Transfers Coverage/Upgrades Salesforce (CRM) to Buy
-
Roth Keeps Ligand (LGND) at Buy; BD Indication for Promacta is Pleasant Surprise
-
Top Image Systems, Ltd. Prices $13.1 Million Public Offering of Ordinary Shares
-
Montage Technology Group Limited Announces Pricing of Follow-On Public Offering
-
Top Image Systems (TISA) to Offer Common Stock
-
Top Image Systems, Ltd. Announces Proposed Public Offering of Ordinary Shares
-
Rexahn Pharma (RNN) Rises Back Above $1 Level with Volume
-
Derma Sciences (DSCI) Prices 6.5M Offering at $11.50/Share
-
Roth Capital Resumes GenVec (GNVC) at Buy; Novartis (NVS) Program Reinvigorates Excitement
-
Tonix Pharma (TNXP) Prices 2.9M Common Offering at $15 Apiece
-
Keryx Biopharma (KERX) Prices 6.9M Offering at $14.50/Share
-
Roth Capital Boosts PT on Keryx Biopharma (KERX) to $30 Following Ferric Citrate Approval in Japan
-
Roth Capital Starts BioCryst Pharma (BCRX) at Buy
-
Roth Capital Starts Paramount Gold and Silver (PZG) at Buy
-
Dendreon (DNDN) Updates Outlook, But Concerns with Provenge Remain; Roth Reiterates 'Sell"
-
Keryx Biopharma (KERX) Well-Positioned for Zerenex Approval in 2014 - Roth Capital
-
Rexahn Pharma (RNN) Announces $20M Registered Direct Offering
-
Regeneron (REGN) Remains Strong Buy Following Recent Positive News - Roth Capital
-
Roth Capital Raises PT on Galena Biopharma (GALE) Following Deal with Dr. Reddy's (RDY)
-
Concert Pharmaceuticals (CNCE) Files $74.75M IPO
-
Notable 52-Week Highs and Lows of the Day 01/13: (RNN) (NVAX) (SWKS) High; (LULU) (SODA) Low
-
Roth Capital Keeps ImmunoCellular (IMUC) at Neutral; Sidelined Until More ICT-107 Answers Appear
-
Applied Genetic Technologies (AGTC) Files $70M IPO
-
Notable Mergers and Acquisitions of the Day 01/13: (BEAM) (GG) (GALE) (FWLT) (VC)/(JCI)
-
Roth Capital Raises PT on Galena Biopharma (GALE) Following Mills Pharmaceuticals Purchase
-
Galena Biopharma (GALE) Acquires GALE-401 Rights Owner, Mills Pharmaceuticals
-
Galena Biopharma Acquires Mills Pharmaceuticals, LLC
-
Retrophin (RTRX) Prices 4.7M Common Offering at $8.50/Share
-
Roth Capital Sees Synta Pharma (SNTA) Ganetespib Trial Updates as Positive; Affirms 'Buy' Rating
-
Notable 52-Week Highs and Lows of the Day 01/09: (RNN) (M) (WAG) High; (MRGE) (LULU) Low
-
Roth Capital Keeps Sunesis Pharma (SNSS) at Buy; Hematology Expansion Positive, Eyes Still on VALOR
-
Roth Capital Starts Rexahn Pharma (RNN) at Buy; Pieces in Place for Ground-Floor Opportunity
-
Notable Analyst Rating Changes 01/09: (JCP) (M) (AET) Upgraded; (BWLD) (S) (NVDA) Downgraded

